(Provided by the applicant) Abstract: Metal catalysts mediate well-controlled, living polymerizations with quantitative initiation and monomer conversion, which facilitates the preparation of polymeric materials with narrow polydispersities and well-defined molecular weights. These well-controlled chemistries, however, show little impact on the formulation of polymeric nanomedicine. Current polymeric nanomedicine still relies on conventional conjugation or encapsulation for drug incorporation, which results in inevitable heterogeneity during nanomedicine formulation. These formulation heterogeneity in particle size, size distribution, drug distribution and variation between batch-to- batch for the drug loading and incorporation efficiency creates tremendous problems for the clinical translations of these nanomedicine delivery vehicles. We propose to study an unprecedented approach to bridge the gap between the control offered by modern polymerization chemistry and the lack of control of current nanomedicine formulation. More specifically, we aim to develop polymer-drug nanoconjugate, a new paradigm of drug delivery nanomedicine with characteristics distinctly different from the current polymeric nanoparticles (nanoencapsulates). In the preparation of polymer-drug nanoconjugates, we use hydroxyl- containing drug molecules as the initiators to mediate a ring-opening polymerization of lactide in the presence of a Mg(II) catalyst. The resulting polylactide-drug conjugate is subsequently nanoprecipitated to form sub-100 nm nanoparticles in uniform size. Compared to current nanoencapsulates, our preliminary study demonstrated that polymeric nanoconjugates show 100% drug incorporation efficiency with pre-definable drug loading by LA/drug ratio. Moreover, nanoconjugates do not show burst drug release, a drawback commonly associated with polymeric nanoencapsulates. Using pyrenemethanol as the model drug, we demonstrated that gram- or larger-scale, highly loaded nanoconjugates can be formulated with several hours. The simplicity for the preparation of large-scale nanoconjugates with controlled loading and release characteristics suggests its great potential for clinical translation. To study the in vivo applicability of nanoconjugates, we propose to develop polylactide-docetaxel nanoconjugates with integrated aptamer ligand for the targeted treatment of the advanced prostate cancer. Public Health Relevance: Polymeric nanoencapsulate as drug delivery vehicles have been investigated for more than 30 years, but only a few of them have been tested clinically and even less been approved by the Food and Drug Administration for clinical applications. We propose to develop nanoconjugates via metal-catalysts mediated, drug-initiated ring-opening polymerization strategy followed by nanoprecipitation.

Agency
National Institute of Health (NIH)
Institute
Office of The Director, National Institutes of Health (OD)
Type
NIH Director’s New Innovator Awards (DP2)
Project #
1DP2OD007246-01
Application #
7981969
Study Section
Special Emphasis Panel (ZGM1-NDIA-O (01))
Program Officer
Basavappa, Ravi
Project Start
2010-09-30
Project End
2015-06-30
Budget Start
2010-09-30
Budget End
2015-06-30
Support Year
1
Fiscal Year
2010
Total Cost
$2,377,500
Indirect Cost
Name
University of Illinois Urbana-Champaign
Department
Engineering (All Types)
Type
Schools of Engineering
DUNS #
041544081
City
Champaign
State
IL
Country
United States
Zip Code
61820
Wang, Hua; Tang, Li; Liu, Yang et al. (2016) In Vivo Targeting of Metabolically Labeled Cancers with Ultra-Small Silica Nanoconjugates. Theranostics 6:1467-76
Azzi, Jamil; Yin, Qian; Uehara, Mayuko et al. (2016) Targeted Delivery of Immunomodulators to Lymph Nodes. Cell Rep 15:1202-13
Yin, Qian; Tang, Li; Cai, Kaimin et al. (2016) Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis. Proc Natl Acad Sci U S A 113:E4601-9
Cai, Kaimin; Yen, Jonathan; Yin, Qian et al. (2015) Redox-Responsive Self-Assembled Chain-Shattering Polymeric Therapeutics. Biomater Sci 3:1061-5
Lee, Jung Seok; Deng, Xiaojian; Han, Patrick et al. (2015) Dual Stimuli-Responsive Poly(β-amino ester) Nanoparticles for On-Demand Burst Release. Macromol Biosci 15:1314-22
Tang, Li; Tong, Rong; Coyle, Virginia J et al. (2015) Targeting tumor vasculature with aptamer-functionalized doxorubicin-polylactide nanoconjugates for enhanced cancer therapy. ACS Nano 9:5072-81
Uckun, Fatih M; Myers, Dorothea E; Cheng, Jianjun et al. (2015) Liposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in Mice. EBioMedicine 2:554-62
Cai, Kaimin; He, Xi; Song, Ziyuan et al. (2015) Dimeric drug polymeric nanoparticles with exceptionally high drug loading and quantitative loading efficiency. J Am Chem Soc 137:3458-61
Zhang, Rujing; Song, Ziyuan; Yin, Lichen et al. (2015) Ionic α-helical polypeptides toward nonviral gene delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 7:98-110
Wang, Hua; Xu, Ming; Xiong, Menghua et al. (2015) Reduction-responsive dithiomaleimide-based nanomedicine with high drug loading and FRET-indicated drug release. Chem Commun (Camb) 51:4807-10

Showing the most recent 10 out of 59 publications